Development and pre-clinical assessment of a first-in-class small molecule inhibitor of FLIP

被引：2
|
作者：
Higgins, Catherine A. [1 ]
Fox, Jennifer [1 ]
Majkut, Joanna [1 ]
Fiedler, Greti E. [1 ]
Roberts, Jamie [1 ]
Humphreys, Luke [1 ]
Boffey, Ray J. [2 ]
Perrior, Trevor R. [2 ]
Harrison, Timothy [1 ]
Longley, Daniel B. [1 ]
机构：
[1] Queens Univ Belfast, Belfast, Antrim, North Ireland
[2] Domainex Ltd, Saffron Walden CB10 1XL, Essex, England
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
基金：
英国惠康基金;
关键词：
D O I：
10.1158/1538-7445.AM2019-382
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
382
引用
收藏
页数：2
相关论文
共 50 条
  • [31] First-in-class: RGS protein inhibitor
    Kimple, A. J.
    Siderovski, D. P.
    MOLECULAR INTERVENTIONS, 2007, 7 (01) : 9 - 9
  • [32] Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1
    Choi, Michael Y.
    Widhof, George F., II
    Wu, Christina C. N.
    Cui, Bing
    Lao, Fitzgerald
    Sadarangani, Anil
    Cavagnaro, Joy
    Prussak, Charles
    Carson, Dennis A.
    Jamieson, Catriona
    Kipps, Thomas J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S167 - S169
  • [33] Pre-clinical and clinical development of the first placental malaria vaccine
    Pehrson, Caroline
    Salanti, Ali
    Theander, Thor G.
    Nielsen, Morten A.
    EXPERT REVIEW OF VACCINES, 2017, 16 (06) : 613 - 624
  • [34] NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor
    Workman, Paul
    CANCER RESEARCH, 2022, 82 (12)
  • [35] The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery Contraction
    Zhang, Yan
    Deng, Jing
    Ma, Sheng
    Xue, Lin
    Zhu, Jin
    Zhu, Wei-liang
    Jiang, Hua-liang
    Li, Jian
    Miao, Li-yan
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (27) : 4258 - 4264
  • [36] Phase I clinical trial of CX-4945: A first-in-class orally administered small molecule inhibitor of protein kinase CK2
    Marschke, Robert F.
    Andreopoulou, Eleni
    Von Hoff, Daniel D.
    Lim, John K. C.
    Padgett, Claire S.
    Northfelt, Donald W.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [37] Radiolabeling and pre-clinical evaluation of a first-in-class CD19 PET Tracer for imaging B cells in multiple sclerosis
    Stevens, Marc
    Cropper, Haley
    Jackson, Isaac
    Chaney, Aisling
    Lechtenberg, Kendra
    Buckwalter, Marion
    James, Michelle L.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [38] Discovery of a first-in-class allosteric inhibitor of the small GTPase Rac1
    Silverman, Robert
    Cooper, Alan
    Kar, Ronodip
    Raman, Mayuri V.
    Ravirala, Ramu
    Shah, Mubarak Hasan
    Mahankali, Sandeep
    Goka, Erik T.
    CANCER RESEARCH, 2024, 84 (06)
  • [39] Development of a first-in-class small molecule inhibitor (EC359) targeting oncogenic LIF/LIFR signaling for the treatment of triple negative breast cancer
    Viswanadhapalli, S.
    Luo, Y.
    Sareddy, G. R.
    Santhamma, B.
    Zhou, M.
    Li, M.
    Pratap, U. P.
    Altwegg, K. A.
    Li, X.
    Srinivasan, U.
    Ma, S.
    Chang, A.
    Riveros, A. C.
    Zhang, K. Y.
    Dileep, K. V.
    Pan, X.
    Murali, R.
    Bajda, M.
    Raj, G.
    Brenner, A.
    Manthati, V.
    Rao, M.
    Tekmal, R. R.
    Nair, H. B.
    Nickisch, K. J.
    Vadlamudi, R. K.
    CANCER RESEARCH, 2019, 79 (04)
  • [40] FDA approves first-in-class AKT inhibitor
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (01) : 9 - 9
12345